Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FUT8 | Q9BYC5 | 1/20 | 0.43 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.32 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.32 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.32 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14084627 | 0.88 | FUT8 (0.42) | FUT8 | |
| SCHEMBL14020359 | 0.87 | FUT8 (0.42) | FUT8 | |
| SCHEMBL14084622 | 0.85 | FUT8 (0.44) | FUT8 | |
| SCHEMBL14084616 | 0.85 | FUT8 (0.42) | FUT8 | |
| SCHEMBL14020352 | 0.85 | FUT8 (0.41) | FUT8 | |
| SCHEMBL14020350 | 0.84 | FUT8 (0.43) | FUT8 | |
| SCHEMBL14084621 | 0.83 | FUT8 (0.32) | FUT8CARM1PRMT1PTPN11 | |
| SCHEMBL14020355 | 0.82 | FUT8 (0.32) | FUT8CARM1PRMT1PTPN11 | |
| SCHEMBL14084614 | 0.79 | PRMT1 (0.41) | ENPP2CARM1PRMT1 | |
| SCHEMBL14084620 | 0.79 | FUT8 (0.39) | FUT8ENPP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7683208-B2 | Bridge compound with N,N-dialkylamino group and application thereof | EVERLIGHT USA, INC. (US) | 2010-03-23 | — | — | US | disclosed |
| US-20090054645-A1 | Bridge compound with N, N-dialkylamino group and application thereof | EVERLIGHT USA, INC. (US) | 2009-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054645-A1 | Bridge compound with N, N-dialkylamino group and application thereof | ALKBH1, ALKBH2, B2M | FUT8 886/4885ENPP2 4800/4885CARM1 421/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.